Suppr超能文献

微量营养素补充剂可调节同型半胱氨酸水平,而与老年受试者的维生素 B 生物状态无关。

A micronutrient supplement modulates homocysteine levels regardless of vitamin B biostatus in elderly subjects.

机构信息

Institute of Food Science and Human Nutrition, Leibniz University Hannover, Germany.

出版信息

Int J Vitam Nutr Res. 2024 Apr;94(2):120-132. doi: 10.1024/0300-9831/a000777. Epub 2023 Jan 30.

Abstract

Elevated homocysteine (Hcy) levels (≥15 μmol/L) in the elderly are frequently associated with a higher risk of cardiovascular disease and cognitive decline. Several studies have already shown an Hcy-lowering effect of B vitamin supplementation in cohorts deficient in these nutrients. The aim of this randomized, double-blinded 12-week intervention study was to investigate whether Hcy levels in healthy elderly subjects (75.4±4.5 years, n=133) could be lowered with a micronutrient supplement (i.e., 400 μg folic acid, 100 μg cobalamin). Difference in mean initial Hcy levels between intervention (17.6±7.1 μmol/L, n=65) and placebo group (18.9±6.1 μmol/L, n=68) was not significant. The prevalence of cobalamin and folate deficiency in the total study population was low: 27% had serum-cobalamin levels ≤150 pmol/L, 12% holo-transcobalamin (Holo-TC) levels ≤50 pmol/L, 13% low cobalamin status using the aggregated cobalamin marker 4cB12 and 10% red blood cell (RBC) folate ≤570 nmol/L. Nevertheless, the treated subjects still showed improved cobalamin and folate biostatus (serum cobalamin Δt-t: 63±48 pmol/L; Holo-TC Δt-t: 17±19 pmol/L; RBC folate Δt-t: 326±253 nmol/L) and Hcy levels (Δt-t: -3.6±5.7 μmol/L). The effects were statistically significant compared to the placebo group with p=0.005 (serum cobalamin), p=0.021 (Holo-TC), p=0.014 (RBC-folate) and p<0.001 (Hcy). The Hcy-lowering effect was dependent on the initial Hcy levels (p<0.001). Our findings suggest that elevated Hcy levels in elderly subjects can be lowered regardless of the initial cobalamin and folate biostatus.

摘要

同型半胱氨酸(Hcy)水平升高(≥15μmol/L)与老年人心血管疾病和认知能力下降的风险增加有关。几项研究已经表明,在缺乏这些营养素的人群中,B 族维生素补充剂具有降低 Hcy 的作用。本随机、双盲、12 周干预研究的目的是探讨健康老年人(75.4±4.5 岁,n=133)的 Hcy 水平是否可以通过微量营养素补充剂(即 400μg 叶酸、100μg 钴胺素)降低。干预组(17.6±7.1μmol/L,n=65)和安慰剂组(18.9±6.1μmol/L,n=68)之间初始 Hcy 水平的平均差异无统计学意义。总研究人群中钴胺素和叶酸缺乏的患病率较低:27%的人血清钴胺素水平≤150pmol/L,12%的人全钴胺素(Holo-TC)水平≤50pmol/L,13%的人使用聚合钴胺素标志物 4cB12 的钴胺素状态较低,10%的人红细胞(RBC)叶酸≤570nmol/L。然而,治疗组仍显示出改善的钴胺素和叶酸生物状态(血清钴胺素Δt-t:63±48pmol/L;Holo-TCΔt-t:17±19pmol/L;RBC 叶酸Δt-t:326±253nmol/L)和 Hcy 水平(Δt-t:-3.6±5.7μmol/L)。与安慰剂组相比,这些效果具有统计学意义,p=0.005(血清钴胺素)、p=0.021(Holo-TC)、p=0.014(RBC 叶酸)和 p<0.001(Hcy)。Hcy 降低的效果取决于初始 Hcy 水平(p<0.001)。我们的发现表明,无论初始钴胺素和叶酸生物状态如何,老年人的 Hcy 水平升高都可以降低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验